[{"from": "human", "value": "Provide a description of this molecule. [B][Branch2][Ring1][=C][C][=C][Branch1][Branch1][C][O][Ring1][Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][Branch2][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][#N][O]"}, {"from": "gpt", "value": "The molecule is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.  This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis."}]